At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 302 enrolled
Drug / intervention
Etokimab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Etokimab and Placebo for Atopic Dermatitis. Completed, enrolled 302 participants across 81 sites in 6 countries.
Detailed Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Czechia, Germany, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedMay 23, 2018
Enrollment StartJun 19, 2018
Primary CompletionDec 3, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.1 years ago
Interventions
Etokimabbiological
Humanized monoclonal antibody, administered by subcutaneous injection
Placebodrug
Administered by subcutaneous injection